EGFR and adenocarcinoma: In patients diagnosed with adenocarcinoma or unspecified NSCLC without activating mutations in the EGFR gene, the status of the ALK and ROS1 genes should be evaluated to detect rearrangements that occur in 3–5% and 1% of patients, respectively [67,68].